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Omeprazole Ameliorates Aspirin-Induced 
Gastroduodenal Injury 
JAMES M. SCHEIMAN, MD, ELIZABETH M. BEHLER, RN, KATHRYN M. LOEFFLER, BS, 
and GRACE H. ELTA, MD 
Aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) damage the gastroduodenal 
epithelium by two mechanisms: direct toxic effects and effects related to the depletion of  
endogenous prostaglandins. The prostaglandin-depleted mucosa has increased sucepti- 
bility to luminal aggressive factors, yet the role of  acid in the pathogenesis of  the NSAID 
ulcer is controversial. In humans, standard doses of  H2-receptor antagonists prevent only 
duodenal injury and provide no protection for the gastric mucosa. It is not known whether 
more potent suppression of  acid can prevent NSAID damage. Twenty healthy volunteers 
were randomized to a double-blind, placebo-controlled, crossover study to determine if 
omeprazole, 40 mg/day prevents gastroduodenal injury due to two weeks of  aspirin 
administration (650 rag four times a day). The severity o f  mucosal injury was quantitated 
by endoscopy and stratified by a scale from 0 (normal) to 4 (ulcer). Fourteen of  the 20 
subjects had less gastric injury during cotherapy with omeprazole. All six with no 
difference received aspirin plus omeprazole in the first treatment period. Omeprazole 
significantly decreased aspirin-induced gastric mucosal injury (P < 0.001, Wilcoxon 
signed-rank test). Omeprazole protected 85% of  subjects from extensive gastric erosions 
(often associated with evidence of  intraluminal bleeding) or ulceration, whereas 70% of  
the subjects developed aspirin-induced grades 3 and 4 gastric injury on placebo (P < O. 01 
by )(2). No subject taking omeprazole developed duodenal injury of  any grade, while 50% 
takingplacebo developed erosions and 15% had ulcer (P < O. 001). Medication side effects 
were mild in the majority of  subjects. Heartburn occurred in seven subjects on aspirin and 
placebo vs one on aspirin and omeprazole (P < O. 01). Salicylate levels were 7. 39 +- 4. 72 
mg/dl (535 +_ 340 lgnol/liter) in the placebo group and 6.95 +_ 4.3 mg/dl (503 +- 311 
izrnol/liter) in the omeprazole group. We conclude that omeprazole, 40 mg/day eliminates 
duodenal injury and markedly ameliorates gastric injury due to administration of  aspirin 
2600 rag~day. Omeprazole prophylaxis of  NSAID injury deserves further study. 
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Aspirin and other nonsteroidal antiinflammatory 
drugs (NSAIDs) are a very common cause of mac- 
roscopic gastric and duodenal mucosal injury. Epi- 
demiologic estimates of NSAID usage suggest that 
up to 1.2% of the United States population use 
these agents daily (1). Given the vast number of 
patients exposed to NSAIDs, their toxicity to the 
upper gastrointestinal tract probably represents the 
most frequent drug side effect in the United States 
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(2). NSAIDs initiate mUcosal injury, culminating in 
ulceration, and promote complications such as 
bleeding and perforation (3). 
Prospective endoscopic studies of rheumatic pa- 
tients receiving chronic aspirin therapy have con- 
firmed a high incidence of both gastric and duodenal 
damage (4, 5). Gastric ulcers were noted in 17%, 
erosions in 40%, with duodenal ulcers and erosions 
seen in 4% and 13%, respectively. Additionally, 
these studies show that NSAID-related gastroduo- 
denal injury correlates poorly with symptoms. The 
absence of symptoms in the presence of NSAID 
injury has ominous potential. NSAID use has been 
implicated as an important risk factor for the devel- 
opment of complicated ulcer disease requiring sur- 
gery (6) or causing death (7). 
NSAIDs are thought to cause mucosal injury via 
two mechanisms. The first is by direct local toxicity 
to mucosa. The second effect is systemically medi- 
ated by cyclooxygenase inhibition, which depletes 
endogenous prostaglandin levels important in the 
maintenance of mucosal integrity. NSAID-induced 
injury in animal models is ameliorated, although not 
prevented by antisecretory agents, suggesting that 
the presence of acid may be required for either the 
direct or systemic toxicity to occur. In a recent 
study utilizing rabbits rendered prostaglandin defi- 
cient with antiprostaglandin antibodies, the mainte- 
nance of intragastric pH > 5 with omeprazole mark- 
edly reduced gastric ulcer formation (8). Whether 
the dictum "no  acid no ulcer" is true for NSAID- 
associated ulcers in humans remains unclear. While 
H2-receptor antagonists have protected against 
short-term (_< 1 week) NSAID administration in nor- 
mal volunteers (9), ranitidine protected only the 
duodenum from NSAID injury in longer-term stud- 
ies in rheumatic patients (10). There is recent evi- 
dence that cotherapy with omeprazole results in a 
dose-dependent reduction in gastric mucosal blood 
loss caused by short-term (two-day) aspirin use 
(11). High-dose omeprazole (40 mg twice a day), 
which results in almost complete acid suppression, 
reduced mucosal blood loss to a level similar to that 
obtained with placebo. 
To further investigate the importance of acid in 
NSAID-induced damage, we studied the effect of 
potent acid suppression with the proton pump in- 
hibitor omeprazole on long-term (two week) aspi- 
fin-induced injury in normal volunteers. Gastroduo- 
denal damage was quantitated endoscopically. 
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TABLE 1. ENDOSCOPIC RATING SCALE 
Grade Endoscopic appearance 
0 normal (erythema included) 
1 -<5 erosions 
2 6-15 erosions 
3 >15 erosions, and/or 
spontaneous bleeding 
4 ulcer 
MATERIALS AND METHODS 
Twenty healthy volunteers between the ages of 18 and 
65 were recruited by advertisement. Criteria for subject 
selection included no history of significant medical prob- 
lems, no regular medication use, no history of gastroin- 
testinal disease, no allergy to aspirin, no alcohol abuse, 
and the absence of recent or regular use of NSAIDs. The 
subjects were randomly assigned to a single capsule con- 
taining either omeprazole 40 mg/day or identical placebo 
(Merck Sharp and Dohme, West Point, Pennsylvania), 
and aspirin 650 mg (two 325-mg tablets, Geneva Generics, 
Broom.field, Colorado) four times per day for two weeks. 
A baseline endoscopy to ensure mucosal integrity was 
performed on all subjects prior to drug administration. On 
the 15th study day, endoscopy was performed to assess 
gastroduodenal damage. All endoscopies were done with 
local oropharyngeal anesthesia (Lidocaine, Astra) and 
intravenous sedation (Versed, Roche) after an overnight 
fast. Both the subjects and endoscopists (J. Scheiman, G. 
Elta) were blinded to the cotherapy, omeprazole versus 
placebo, with aspirin. Prior to endoscopy, serum was 
obtained for measurement of salicylate levels reflecting 
blood concentrations approximately 10 hr after the pre- 
ceding dose of aspirin. 
After a two-week period to "wash out" the drug, a 
second baseline endoscopy was performed to ensure mu- 
cosal integrity. Subjects were then crossed over to either 
omeprazole or placebo plus aspirin for an additional two 
weeks. To ensure healing of prior injury, a few subjects 
with severe damage were given a brief course of antacid 
therapy (30 cc four times a day for five days) during the 
wash-out period. Medication compliance was confirmed 
by pill count of returned medication at the end of each 
treatment period. The protocol and consent form for this 
study were reviewed and approved by the Human Use 
Committee, Ann Arbor, Michigan. 
Endoscopic Scoring System. Endoscopic injury was 
quantitated by the endoscopic rating scale described in 
Table 1. An erosion was defined as a white-based lesion 
<4 mm in length surrounded by erythematous mucosa. 
Ulcers were defined as circumscribed breaks in the mu- 
cosa with appreciable depth _>4 mm in size. The presence 
of fresh or old blood in the stomach or duodenum was also 
noted. Subjects kept a diary to report the symptoms of 
abdominal pain, heartburn, nausea, vomiting, tarry stool, 
skin rash, tinnitus, diarrhea, and headache. The intensity 
was rated as mild, moderate, severe, and intolerable on a 
1-4 scale. Subjects completed a baseline symptom score 
reflecting these symptoms in the previous year and also 
during the two-week period off all medications. 
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TABLE 2. POSTTREATMENT GASTRIC MUCOSAL SCORES 
Score 
Treatment 0 1 2 3 4 Total 
Placebo 0 1 5 9 5 20 
Omeprazole 40 mg/day 8 3 6 2 1 20 
TABLE 3. GASTRIC THERAPEUTIC SUCCESS RATE* 
Treatment Protection No Protection Total 
Placebo 2 (10%) 18 20 
Omeprazole 40 mg/day 11 (55%)'I" 9 20 
*Score of <1 = protection. 
tP  < 0.01 by X 2. 
Statistical Methods. The use of a double-blind, cross- 
over design allows analysis of the distribution of the 
paired injury scores  in the omeprazole  and placebo 
groups by the Wilcoxcon signed-rank test. For  the pur- 
poses of the study, clinically significant protection by  
omeprazole was defined as a score of _<1 for the gastric 
mucosa and 0 for duodenal mucosa.  The efficacy for 
omeprazole protection was analyzed using ×2 test with 
Yates '  correction. Salicylate levels were compared by the 
Student 's  t test for paired data. 
RESULTS 
Twenty-six subjects entered the study and 20 
subjects completed it. The 20 volunteers included 
11 men and 9 women with an age range of 18-44 
years (mean --. SD was 27 -- 6 years). Only two 
female subjects (10%) smoked cigarettes, smoking 
4-10 cigarettes per day. Ethanol use was not pro- 
scribed for this study. The distribution of ethanol 
use during the study was: 40%, none; 15%, 1 drink/ 
week; 30%, 2-3 drinks/week; 15%, 8-20 drinks/ 
week. Two subjects were dropped due to baseline 
erosion on entry endoscopy. Two subjects were 
dropped due to medication noncompliance (aspi- 
rin), and one for personal reasons. One subject in 
the omeprazole arm dropped due to rash and facial 
puffiness. Analysis of returned medications indi- 
cated that 90% of the subjects took all medications 
prescribed; two subjects missed one to three days 
of medications. 
Prevention of Gastric Lesions. The distribution of 
posttreatment gastric endoscopic scores is shown in 
Table 2. A plot of individual gastric scores for each 
subject is shown in Figure 1. Fourteen of 20 sub- 
jects had less injury on omeprazole 40 rag/day vs 
placebo. There were six subjects who had no dif- 
ference in gastric injury, all received ASA and ome- 
prazole in the initial treatment period before cross- 
over. No subject had greater injury on omeprazole. 
Omeprazole significantly decreased gastric mucosal 
injury score due to aspirin, 650 mg four times a day, 
compared to placebo (P < 0.001). 
Table 3 summarizes the therapeutic success rate 
for gastric protection by omeprazole. Applying a 
rigorous definition to therapeutic success with a 
score <1 (<5 erosions), omeprazole significantly 
protected the gastric mucosa in 55% vs 10% of 
subjects (P < 0.01). Aspirin induced extensive ero- 
sive injury, which was frequently associated with 
endoscopic evidence of intraluminal bleeding or ul- 
ceration (grades 3 and 4 injury) in 70% of placebo 
subjects compared to 15% of subjects on omepra- 
zole cotherapy (P < 0.001). 
Table 4 summarizes the final duodenal endo- 
scopic score for the subjects. No subject taking 
omeprazole developed aspirin-induced duodenal in- 
jury, a therapeutic success rate of 100%. Fifty per- 
cent of subjects on placebo developed duodenal 
A 
0 0 
Placebo Omepmzole Placebo Omepmzole 
Fig 1. Final gastric injury scores for the 20 subjects. (A) Subjects receiving aspirin + 
placebo initially. (13) Subjects receiving aspirin + omeprazole initially. Analysis of all 
subjects demonstrates omeprazole significantly decreases gastric injury (P < 0.001, 
Wilcoxon signed-rank test). 
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TABLE 4. PosTrREATMENT DUODENAL MUCOSAL SCORES 
Score 
Treatment 0 1 2 3 4 Total 
Placebo 10 4 2 1 3 20 
Omeprazole 40 mg/day 20 0 0 0 0 20 
erosions, and 15% developed frank ulceration (P < 
0.01, Wilcoxon signed rank test). 
Adverse Symptoms. Medication side effects were 
mild in the majority of subjects. One subject was 
dropped from the protocol due to a possible drug 
reaction with skin rash and facial puffiness while 
taking aspirin and omeprazole. Tinnitus was noted 
in three subjects, prompting a reduction in aspirin 
dose to three times a day in one subject taking 
placebo, with resolution of symptoms. Two sub- 
jects noted nausea, one taking placebo. Abdominal 
pain occurred in five subjects on placebo and in four 
on omeprazole; pain intensity was similar in both 
groups. Heartburn was the most frequent com- 
plaint, which occurred in seven subjects taking as- 
pirin and placebo vs one subject taking cotherapy 
with omeprazole, a significant difference (P _< 0.01 
by ×2). There was no correlation between symptoms 
and ~ endoscopic scores. The remainder of reported 
symptoms were rare and of equal frequency prior to 
and off all medications versus during treatment. 
Salieylate Levels. Salicylate levels were 7.39 __+ 
4.72 mg/dl (535 ___ 340 i~mol/liter) in the placebo 
group and 6.95 --- 4.28 mg/dl (503 --- 311 ~mol/liter) 
in the omeprazole group. There was no significant 
difference in salicylate levels in the two groups or 
any correlation between salicylate level and endo- 
scopic injury score. 
DISCUSSION 
Strategies to prevent injury from aspirin and 
other NSAIDs have evolved from our understand- 
ing of the combination of local and systemic mech- 
anisms of mucosal injury (12). To avoid local tox- 
icity, enteric coating and prodrugs that bypass 
gastric absorption have been utilized. Although mu- 
cosal damage appears diminished by this strategy, 
the systemically mediated depletion of gastroduo- 
denal prostaglandins still makes these agents ul- 
cerogenic. It has been suggested that NSAID- 
induced inhibition of prostaglandin synthesis is 
unlikely to cause damage p e r  se, but causes the 
mucosa to be more susceptible to injury by acid, 
bile salts, or ethanol (13). Since prostaglandin de- 
pletion is fundamental to the pathogenesis of the 
NSAID ulcer, prophylactic replacement of exoge- 
nous prostaglandins is logical (14). The oral PGE1 
analog misoprostol is currently the only agent 
proven effective in the prevention of gastric ulcers 
in patients taking NSAIDs. However, drug-induced 
diarrhea and abdominal discomfort limit both phy- 
sician and patient acceptance of misoprostol. Diar- 
rhea occurs in up to 39% of patients taking miso- 
prostol, although lower doses (100 ~g four times a 
day) are better tolerated. These side effects may 
lead to rates of drug discontinuation above the 5% 
reported in clinical trials (3). Given the limitations 
in patient and physician acceptance of oral prosta- 
glandins, a search for other prophylactic strategies 
for NSAID ulceration seems worthwhile. 
The efficacy of traditional doses of H2-receptor 
antagonists for healing of NSAID-induced ulcers 
despite continued NSAID use is controversial. Re- 
cently, a large multicenter study showed profound 
acid inhibition using high-dose (40 mg/day) omepra- 
zole was effective in the treatment of NSAID- 
associated gastric ulcers (15). The healing and re- 
lapse rate of three treatment regimens for benign 
gastric ulcer were compared: 40 mg omeprazole 
every day, 20 mg omeprazole every day, and 150 
mg ranitidine twice a day. Analysis of the subgroup 
with NSAID-associated ulcers who continued to 
receive concurrent  NSAIDs showed four-week 
healing rates of 81% in the 40 mg/day omeprazole 
group, 61% in the 20 mg/day group, and 32% in 
those treated with ranitidine. At eight weeks, the 
percentages healed were 95, 82, and 53%. There 
was also significantly less relapse of both symptoms 
and ulceration in the omeprazole-treated groups at 
six-month follow-up off all medication. The ability 
to heal NSAID ulcers with acid suppression while 
NSAIDs are continued suggests that NSAID- 
induced ulcers depend on acid-peptic activity. Per- 
haps the prostaglandin-depleted mucosa is so sen- 
sitive to acid injury that more acid inhibition is 
required than obtained with H2-receptor antago- 
nists both for healing of established ulcers despite 
continued NSAID use and for prophylaxis of ulcer 
formation. 
We studied normal volunteers to determine the 
efficacy of omeprazole 40 mg/day for the prevention 
of chronic (two-week) gastroduodenal damage from 
2600 mg/day of aspirin. It is controversial whether 
volunteer studies can predict efficacy of therapies 
designed to prevent NSAID ulceration. However, it 
has been observed that NSAID doses that produce 
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significant injury in volunteers tend to cause similar 
injury in patients (16). The advantages of volunteer 
studies are that they are faster to complete and 
potentially safer than those in patients. The normal 
volunteer studies comparing the efficacy of miso- 
prostol vs H2-receptor antagonists for the preven- 
tion of NSAID injury had similar results to the 
subsequent studies in arthritic patients. Unfortu- 
nately, lack of injury in short-term studies has not 
always correlated with a lack of injury in patients on 
longer-term therapy (9, 10). Aspirin-induced injury 
decreases despite continued administration, an ef- 
fect known as "gastric adaptation" (17). This re- 
duction in injury begins immediately after aspirin 
administration and occurs in two to eight weeks 
(median 4.5 weeks) in subjects taking 650 mg four 
times a day (18). The somewhat intermediate two 
week treatment period in this study was chosen to 
allow volunteer compliance. 
Aspirin inhibits cyclooxygenase, depletes en- 
dogeneous prostaglandins, and produces the most 
dramatic acute topical injury of the NSAIDs. The 
dissociation constant of aspirin is 3.5; typical 
NSAIDs have ionization constraints in the 3-5 
range. In the presence of acid, these drugs are 
nonionized and freely diffuse across cell mem- 
branes. Once inside the cell, the elevated intracel- 
lular pH promotes dissociation to the ionized form. 
Once ionized, aspirin remains water soluble and 
trapped intracellularly. Because the nonionized 
form remains in equilibrium across the cell mem- 
brane, the total intracellular drug concentration 
(ionized and nonionized) will be much higher than 
outside the cell, an effect known as ion trapping 
(19). Ion trapping allows direct cellular injury due 
to the toxicity of high intracellular levels of salicy- 
late. These toxic effects lead to abnormal ion flux 
across the epithelium, with increased H ÷ back- 
diffusion occurring rapidly. These changes in mem- 
brane permeability may be secondary to impair- 
ment of cellular energy metabolism (13). Other 
NSAIDs appear to damage mucosa through similar 
mechanisms, although quantitative levels of topical 
injury among NSAIDs vary considerably. Extrapo- 
lation of our data regarding the ability of omepra- 
zole to ameliorate injury caused by NSAIDs other 
than aspirin requires experimental confirmation. 
Acid suppression may decrease topical injury to 
aspirin by raising intragastric pH to maintain salic- 
ylate in its ionized form. Alternatively, acid sup- 
pression may decrease local damage by simply de- 
creasing hydrogen ion back diffusion. The ability of 
high-dose (40 mg twice a day) omeprazole therapy 
to abolish short-term aspirin-induced (900 mg twice 
a day for two days) gastric blood loss suggests that 
the presence of luminal acid is important for initia- 
tion of NSAID ulceration. Omeprazole 20 mg/day in 
the same protocol significantly prevented aspirin- 
induced blood loss but was less effective than the 
higher dose (11). Long-term use of omeprazole at 80 
mg/day is currently impractical, prompting us to 
choose 40 mg/day. 
Omeprazole 40 mg/day significantly prevented 
both gastric and duodenal injury due to 2600 mg 
aspirin/day over the two-week period of our study. 
Since our endoscopic score is arbitrary, the defini- 
tion of therapeutic efficacy is a matter of judgment. 
Omeprazole 40 mg/day prevented 95% of subjects 
from developing ulceration, 85% from having >15 
erosions (all <3 mm in size), and 55% from having 
>5 erosions. In the subjects given placebo, 25% 
developed gastric ulcers, 70% had grade 3 injury or 
worse, and all 95% had at least grade 2 injury. 
Omeprazole was 100% effective in preventing duo- 
denal injury. Skeptics question the importance of 
preventing erosions in the absence of direct evi- 
dence linking erosions to chronic ulcers. However, 
in a recent trial comparing the efficacy of misopros- 
tol vs sucralfate for the prevention of NSAID ul- 
cers, the presence of erosions upon study entry was 
associated with an increased risk of gastric ulcer 
(20), suggesting that erosions may develop into 
chronic ulcers with continued NSAID exposure. A 
study of longer duration in chronic NSAID users is 
necessary to determine if the observed decrease in 
aspirin-induced gastric and duodenal injury by ome- 
prazole cotherapy reduces the number of chronic 
ulcers and their associated complications. 
Omeprazole 40 mg/day, a dose that decreases 
basal acid output by 80-93% and decreases intra- 
gastric acidity by 92-94%, markedly ameliorated 
gastric injury due to aspirin. This effect appears to 
have occurred independent of a major influence 
upon salicylate absorption, since serum levels were 
not significantly different in each arm of the study. 
Only a detailed pharmacokinetic study could ensure 
the absence of any effect of omeprazole on aspirin 
absorption. The continued presence of injury in 
humans during this degree of acid suppression sug- 
gests that virtual anacidity, as observed with aboli- 
tion of aspirin microbleeding with 80 mg omepra- 
zole/day, is required to prevent all of the acute 
topical injury of aspirin. Since we did not quantitate 
acid secretion in our subjects and there is known 
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interindividual variability in omeprazole's ability to 
inhibit acid secretion (21), it is possible that the six 
subjects who developed equivalent levels of dam- 
age on omeprazole and placebo had weaker acid 
suppression. Furthermore, since omeprazole serum 
levels were not measured, absolute compliance can- 
not be confirmed. An alternative explanation for the 
lack of gastroprotection in five subjects is gastric 
adaptation. All of the subjects receiving placebo 
and aspirin in the initial treatment period had re- 
duced gastric injury on omeprazole, six by two 
grades and three by one grade. In contrast, all six 
subjects who developed identical injury on placebo 
and omeprazole received cotherapy with omepra- 
zole initially, including the subject who developed 
ulceration. Although the two-week wash-out period 
was designed to allow wash-out of omeprazole (21), 
it is possible that adaptive processes stimulated by 
two weeks of aspirin therapy remained activated 
and prevented the even more severe damage that 
would have occurred with aspirin and placebo. 
Adverse effects in this study were uncommon.  
Two subjects developed a rash on omeprazole. This 
prompted discontinuation of study participation in 
one subject, but without rechallenge a definite rela- 
tionship to omeprazole is uncertain. The other sub- 
jects '  rash resolved during continued treatment. All 
other side effects were nearly identical in both treat- 
ment phases. Omeprazole significantly ameliorated 
heartburn related to aspirin uptake, an effect not 
observed with misoprostol prophylactic therapy. 
Is long-term therapy with omeprazole, in doses of 
20-40 mg/day, a practical consideration? The drug 
is costly and long-term use has not been proven to 
be safe. Pronounced acid inhibition leads to hyper- 
gastrinemia and increases the risk of enterochromaf- 
fin-like cell hyperplasia with a theoretical increased 
risk of carcinoid tumor formation. Furthermore,  
prolonged hypochlorhydria can lead to bacterial 
overgrowth and increased nitrosamine levels and a 
theoretical increased risk of gastric cancer (21). 
However,  patients with Zollinger-Ellison syndrome 
have received this drug long-term, and its adverse 
effect profile has been similar to placebo or H 2- 
receptor antagonists (22). Additionally, omeprazole 
can induce cytochrome P-450 IA2 ha hepatocytes 
(23) and IA1 in the proximal gastrointestinal epithe- 
lium (24), raising the question of increased potential 
for carcinogenesis. This speculation remains totally 
hypothetical (25). No evidence for genotoxicity of 
omeprazole has been observed in recently pub- 
lished investigations (26). NSAID injury leads to 
70000 hospitalizations and 7000 deaths annually in 
the United States (27). The population at greatest 
risk for NSAID-induced damage is elderly, thus 
exposure to very long-term omeprazole may be 
limited. Further studies are needed to ascertain the 
efficacy of omeprazole prophylaxis of NSAID in- 
jury and determine if the benefits of this therapy 
outweigh its risk and cost. 
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